TY  - JOUR
TT  - CYP2C9 ACTIVITY IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR-ALPHA (TNFα) BLOCKERS
AU  - Kara, Halil
AU  - Özer, Erdem K.
AU  - Goktas, Mustafa Tugrul
AU  - Gezer, İlknur Albayrak
AU  - Yasar, Umit
PY  - 2017
DA  - February
JF  - The Turkish Journal Of Occupational / Environmental Medicine and Safety
JO  - turjoem
PB  - Engin TUTKUN
WT  - DergiPark
SN  - 2149-4711
SP  - 59
EP  - 59
VL  - Volume 2
IS  - İssue 1 (1)
KW  - CYP2C9 ACTIVITY IN ANKYLOSING SPONDYLITIS PATIENTS TREATED WITH TUMOR NECROSIS FACTOR-ALPHA (TNFα) BLOCKERS
N2  - Ankylosing spondylitis (AS) is a chronicinflammatory disease. AS is mainly characterized by inflammation, especiallyincrease of the proinflammatory cytokines such as, TNF-α, IL-6, IL-17 andIL-23. Tumor necrosis factor-alpha (TNFα) blockers, for example, etanercept,infliximab, golimumab and adalimumab are used for the treatment of AS. In aprevious study, we found that CYP2C9 enzyme activity was lower in AS patientscompared to the healthy volunteers. This work purposes to compare the phenotypeof CYP2C9 in Anti-TNF user and non-user AS patients.A total of 32 patients with AS (11Anti-TNF user, 21 non-users) were recruited in the study. A single 50 mglosartan was given to the participants and 8-hr urine was collected overnight.Then, the urinary concentrations of losartan and its metabolite, E3174, weremeasured by high-pressure liquid chromatography. Urinary losartan/E3174metabolic ratio was used as an index of CYP2C9 enzyme activity. Differences inthe metabolic ratio of losartan was compared with Mann–Whitney U test.The mean values of losartan metabolic ratiowere 2.14 and 2.33 in Anti-TNF user and non-user AS patients (p=0.51, medianand 95% CI: 1.27 [0.92-3.35] and 1.84 [1.48-3.18], respectively).CYP2C9 enzyme activity was similar inAnti-TNF user and non-user, therefore anti-TNF drugs do not seem to interactwith CYP2C9 substrates. 
CR  - Yildirim Beyazit University, Faculty of Medicine, Department of Pharmacology, Ankara, Turkey
CR  - Selçuk University, Faculty of Medicine, Department of Pharmacology, Konya, Turkey
CR  - Selçuk University, Faculty of Medicine, Department of Physical Medicine and Rehabilitation, Konya, Turkey
CR  - Hacettepe University, Faculty of Medicine, Department of Pharmacology, Ankara, Turkey
UR  - https://dergipark.org.tr/tr/pub/turjoem/issue//304026
L1  - https://dergipark.org.tr/tr/download/article-file/291092
ER  -